Evidence map›Paper›PMID 32882637›Full record

ArticleVirology2020

Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Ki-Hye Kim, Yu-Jin Jung, Youri Lee, Bo Ryoung Park, Judy Oh, Yu-Na Lee, Min-Chul Kim, Subbiah Jeeva, Sang-Moo Kang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Physical radiofrequency adjuvant enhances immune responses to influenza H5N1 vaccination.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Ki-Hye KimCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Yu-Jin JungCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Youri LeeCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Bo Ryoung ParkCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Judy OhCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Yu-Na LeeCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA; Animal and Plant Quarantine Agency, Gimcheon, 39660, Republic of Korea.
Min-Chul KimCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA; CARESIDE Co., Ltd., Seongnam, Gyeonggi-do, Republic of Korea.
Subbiah JeevaCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Sang-Moo KangCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA. Electronic address: skang24@gsu.edu.
Georgia State University · USInstitute of Infection and Immunity · CA

Funding

Influenza vaccines inducing broadly cross protective immunityR01AI093772 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2011 to 2020
$4.2M
Universal epitopes-based recombinant influenza vaccinesR21AI147042 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2020 to 2021
$428k
Multi NA-based influenza vaccinesR41AI152800 · NIAID · ADVAC, LLC · PI KANG, SANG-MOO · 2020 to 2020
$272k
NIAID NIH HHS R01 AI093772NIAID NIH HHS R21 AI147042NIAID NIH HHS R41 AI152800
6 · The paper itself

Abstract

Influenza virus neuraminidase (NA) contains a universally conserved epitope (NAe, NA

Indexed as

AnimalsAntibodies, ViralCross ProtectionEpitopesFemaleHemagglutinin Glycoproteins, Influenza VirusHumansImmunity, CellularImmunity, HumoralInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza A Virus, H9N2 SubtypeInfluenza VaccinesMiceMice, Inbred BALB CAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza Virushemagglutinin, human influenza A virusInfluenza VaccinesM2 protein, Influenza A virusNeuraminidaseRecombinant Fusion ProteinsVaccines, InactivatedViral Matrix ProteinsViroporin ProteinsCross protectionHeterosubtypic immunityM2 extracellular domain epitopeNeuraminidase epitopeRecombinant chimeric influenza virus

Identifiers

PMID32882637
PMCPMC7554235
OpenAlexW3080841074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.